Duloxetine News and Research

RSS
Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults aged 18 years and older. Duloxetine is not approved for use in pediatric patients.
Antidepressants used for chronic pain relief come with significant side effects

Antidepressants used for chronic pain relief come with significant side effects

Antidepressants and anti-seizure drugs can effectively treat diabetic nerve pain, research finds

Antidepressants and anti-seizure drugs can effectively treat diabetic nerve pain, research finds

Study reports presence of structural changes in the brain during medication treatment for depression

Study reports presence of structural changes in the brain during medication treatment for depression

New position statement offers recommendations for physicians on prevention of diabetic neuropathy

New position statement offers recommendations for physicians on prevention of diabetic neuropathy

Functional MRI brain scan may help predict patient’s response to antidepressant therapy

Functional MRI brain scan may help predict patient’s response to antidepressant therapy

Depression drug can alleviate joint pain in postmenopausal women treated for breast cancer

Depression drug can alleviate joint pain in postmenopausal women treated for breast cancer

Combination approach could be more effective to treat fibromyalgia pain

Combination approach could be more effective to treat fibromyalgia pain

Most antidepressants are ineffective at treating children and teens, study shows

Most antidepressants are ineffective at treating children and teens, study shows

Nutritional supplements can enhance effectiveness of antidepressants

Nutritional supplements can enhance effectiveness of antidepressants

Botulinum toxin A injections combat neuropathic pain

Botulinum toxin A injections combat neuropathic pain

Unmet medication need in neuropathic pain

Unmet medication need in neuropathic pain

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

AVACEN Medical launches $2M campaign in response to positive outcomes of fibromyalgia study

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

IQWiG completes first health economic evaluation

IQWiG completes first health economic evaluation

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Duloxetine drug alleviates pain from chemotherapy

Duloxetine drug alleviates pain from chemotherapy

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients